Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute, Inc. (RZLT) announced a late-breaking oral presentation of its Phase 2b RIZE Study data for RZ358 at the Pediatric Endocrine Society Annual Meeting on May 1, 2022. The study focused on congenital hyperinsulinism (HI), evaluating RZ358's safety, tolerability, and glycemic efficacy in patients inadequately controlled by existing therapies. Dr. Paul Thornton will present findings, with the conference call set for 2:30 p.m. ET on the same day. Rezolute aims to disrupt treatment paradigms for metabolic diseases with innovative therapies.
Rezolute, Inc. (Nasdaq: RZLT) has joined the Rare Disease Company Coalition, an alliance of life science firms focused on developing treatments for rare diseases. This collaboration aims to address challenges in rare disease drug development and advocate for supportive government policies. CEO Nevan Charles Elam highlighted the importance of the coalition in fostering understanding among stakeholders. Rezolute is committed to innovating treatments for severe metabolic diseases, with its lead asset, RZ358, in late-stage development for congenital hyperinsulinism.
Rezolute, Inc. (RZLT) announced positive results from its Phase 2b RIZE study of RZ358, aimed at treating congenital hyperinsulinism. The study demonstrated significant improvements in hypoglycemia, along with good safety and tolerability. A total of 23 patients were involved in the study, evaluating RZ358's efficacy over 8 weeks. The promising results will be presented at a medical congress in 2Q 2022, followed by a conference call to discuss findings. The company plans to advance RZ358 to Phase 3 trials, underlining its commitment to innovative treatments for rare diseases.
Rezolute, Inc. (RZLT) announced positive topline data from its Phase 1b multiple-ascending dose study of RZ402, an oral plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). The study demonstrated dose-dependent increases in systemic exposure, with RZ402 surpassing target concentrations significantly. The therapy is poised to transform DME treatment, reducing patient invasiveness. No serious adverse events were reported, bolstering RZ402's safety profile. A Phase 2 proof-of-concept study is expected in the second half of 2022.
Rezolute, Inc. (RZLT) reported its financial results for Q2 fiscal 2022, ending December 31, 2021, revealing cash and cash equivalents of $77.4 million. The company raised $56 million in Q4 2021 through stock offerings. R&D expenses rose to $9.5 million due to increased clinical trial and manufacturing costs, while G&A expenses remained flat at $2.7 million. The net loss for the quarter was $12.6 million, or $0.80 per share, compared to a net loss of $7.1 million, or $0.88 per share, in the previous year. Topline results for lead programs RZ358 and RZ402 are expected by end of Q1 2022.
Rezolute, Inc. (Nasdaq: RZLT) reported its financial results for Q1 FY2022, ending September 30, 2021. The company raised $55 million in a recent offering, strengthening its balance sheet and extending its cash runway. Key developments include ongoing enrollment in Phase 2b trials for RZ358 and Phase 1b for RZ402, with topline results expected in Q1 2022. Cash and equivalents stood at $37.3 million. However, R&D expenses rose significantly to $5.8 million from $2.3 million YoY, contributing to a net loss of $7.8 million, or $0.92 per share, compared to $3.6 million, or $0.62 per share, last year.
Rezolute, Inc. (Nasdaq: RZLT) announced the pricing of an underwritten public offering of 6,030,847 shares at $6.50 each, along with pre-funded warrants for 1,661,461 shares at $6.49 each. Additionally, a registered direct offering of 769,231 shares at $6.50 each will occur. The total anticipated proceeds are about $55 million, to fund clinical research, development, and general corporate purposes. The offerings will close approximately on October 15, 2021, pending customary conditions. Oppenheimer & Co. is the sole bookrunning manager for the public offering.
Rezolute, Inc. (Nasdaq: RZLT) announced plans for an underwritten public offering of common stock and pre-funded warrants, alongside a direct offering to institutional investors. This initiative aims to generate capital for clinical research, development, and general corporate purposes. The company is granting underwriters a 30-day option to purchase additional shares. The offerings are subject to market conditions and will utilize an effective shelf registration statement filed with the SEC. Rezolute's lead product, RZ358, is in Phase 2b for congenital hyperinsulinism.
Rezolute, Inc. (Nasdaq: RZLT) presented a natural history study revealing significant hypoglycemia in patients with congenital hyperinsulinism during the European Society for Paediatric Endocrinology 2021. The study involved 22 patients, showing mean hypoglycemia durations of over 2.5 hours daily. Notably, hypoglycemia levels exceeded recommended guidelines, raising concerns about long-term consequences such as developmental delays. Rezolute is advancing its Phase 2b RIZE study of RZ358, a monoclonal antibody aimed at addressing this condition, with topline results expected in Q1 2022.
Rezolute, Inc. (RZLT) reported its financial results for Q4 and full fiscal year 2021, highlighting progress in clinical programs such as RZ358 and RZ402. As of June 30, 2021, cash reserves stood at $41 million. R&D expenses rose to $4.4 million for Q4, up from $2.4 million in the previous year, totaling $15 million for the year. G&A expenses also increased to $2.2 million in Q4, leading to a net loss of $6.5 million for the quarter and $20.9 million for the full year. The company anticipates topline data for RZ358 and RZ402 in Q1 2022.